Clinical Research Directory
Browse clinical research sites, groups, and studies.
RANK-ligand Inhibition to Combat Sarcopenia with Underlying Osteoporosis
Sponsor: Prince of Wales Hospital, Shatin, Hong Kong
Summary
The objective of this study was to conduct a randomized, double-blind, double-dummy active controlled trial to determine the efficacy of denosumab in treating sarcopenia with underlying osteoporosis.
Official title: RANK-ligand Inhibition to Combat Sarcopenia with Underlying Osteoporosis: a Randomized, Double-blind, Double-dummy, Active-Controlled Trial
Key Details
Gender
All
Age Range
65 Years - Any
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2024-04-09
Completion Date
2027-10
Last Updated
2024-10-16
Healthy Volunteers
No
Conditions
Interventions
Denosumab
60mg subcutaneous Denosumab (1mL solution) every 6 months and intravenous placebo (100mL normal saline) once yearly
Zolendronic Acid
5mg intravenous Zoledronic Acid (100mL solution) once yearly and subcutaneous placebo (1mL normal saline) every 6 months
Locations (1)
The Chinese University of Hong Kong
Hong Kong, China